Literature DB >> 7557621

Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis.

D S McMeekin1, R A Burger, A Manetta, P DiSaia, M L Berman.   

Abstract

In order to better understand the clinical presentation and biologic behavior of ovarian carcinomas arising in endometriosis, we performed a historical cohort study of all women with endometrioid adenocarcinoma of the ovary (ECO) diagnosed between 1979 and 1991 at our institutions. A review of pathology reports determined the presence or absence of coexisting endometriosis. Cancers adjacent to endometriosis on the same ovary or arising within endometriosis were labeled endometriosis-associated endometrioid adenocarcinoma (EAEA), while all others were considered typical endometrioid adenocarcinoma (TEA). Associations between tumor type and clinicopathologic variables were analyzed by chi 2 and Fisher's exact tests as indicated. Disease-free interval (DFI) and overall survival were estimated using the Kaplan-Meier method. The independent prognostic significance of clinicopathologic variables was determined by multivariate analysis using the Cox proportional hazards regression model. Of 91 ECO patients identified, 63 (69%) had TEA and 28 (31%) had EAEA. Significant differences between TEA and EAEA existed for age at diagnosis (greater than 55 years; 56 vs 32%, P = 0.039), nulliparity (19 vs 46%, P = 0.007), stage (I and II combined; 37 vs 70%, P = 0.004), and disease status at completion of primary surgery (complete tumor resection; 47 vs 70%, P = 0.04). Synchronous atypical endometrial hyperplasia or uterine carcinoma was found in 7/63 (11%) TEA versus 7/28 (25%) EAEA cases (P = 0.054). Estimated 5-year DFI by life table analysis was significantly longer in the EAEA than in the TEA cohorts (57 vs 25%, P = 0.02); however, the 5-year survival difference was not significant (59 vs 45%, P = 0.18). Multivariate analysis identified only stage as an independent prognostic factor in predicting both DFI and survival. In conclusion, women with EAEA are significantly younger, present with earlier stage disease, and have a longer disease-free survival than those with TEA. These factors may reflect a more favorable biologic behavior of ECO when arising in association with endometriosis.

Entities:  

Mesh:

Year:  1995        PMID: 7557621     DOI: 10.1006/gyno.1995.1271

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

Review 1.  Ovarian cancer in endometriosis: clinical and molecular aspects.

Authors:  B Lyttle; L Bernardi; M E Pavone
Journal:  Minerva Ginecol       Date:  2014-04

Review 2.  Better therapeutic trials in ovarian cancer.

Authors:  Michael A Bookman; C Blake Gilks; Elise C Kohn; Karen O Kaplan; David Huntsman; Carol Aghajanian; Michael J Birrer; Jonathan A Ledermann; Amit M Oza; Kenneth D Swenerton
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

3.  Identification of cells with colony-forming activity, self-renewal capacity, and multipotency in ovarian endometriosis.

Authors:  Rachel Wah Shan Chan; Ernest Hung Yu Ng; William Shu Biu Yeung
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

4.  Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis.

Authors:  Koji Yamanoi; Masaki Mandai; Ayako Suzuki; Noriomi Matsumura; Tsukasa Baba; Yumiko Yoshioka; Kenzo Kosaka; Ikuo Konishi
Journal:  Oncol Lett       Date:  2012-06-22       Impact factor: 2.967

5.  Synchronous endometrioid endometrial and ovarian cancer in a 34-year-old woman.

Authors:  Patrícia Isidro Amaral; Abel Silva; Abílio Lacerda; Carlos Barros
Journal:  BMJ Case Rep       Date:  2015-09-08

6.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

Review 7.  Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.

Authors:  Masaki Mandai; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

Review 8.  Precursors of endometrial and ovarian carcinoma.

Authors:  Robert J Kurman; Thomas G McConnell
Journal:  Virchows Arch       Date:  2009-10-27       Impact factor: 4.064

9.  Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Authors:  Murray Joseph Casey; Chhanda Bewtra; Henry T Lynch; Carrie Snyder; Mark Stacy; Patrice Watson
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

Review 10.  MR imaging in ovarian cancer.

Authors:  S A A Sohaib; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.